234 related articles for article (PubMed ID: 23599157)
21. TRPS1 expression in primary and metastatic prostatic adenocarcinoma, muscle invasive bladder urothelial carcinoma, and breast carcinoma: Is TRPS1 truly specific and sensitive for a breast primary?
Bachert SE; Di J; Zhang S; Short HE; Piecoro DW; McDonald RJ; Myint ZW; Hensley PJ; Allison DB
Hum Pathol; 2024 Jan; 143():42-49. PubMed ID: 38052269
[TBL] [Abstract][Full Text] [Related]
22. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.
Volmar KE; Chan TY; De Marzo AM; Epstein JI
Am J Surg Pathol; 2003 Sep; 27(9):1243-52. PubMed ID: 12960809
[TBL] [Abstract][Full Text] [Related]
23. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases.
Lionti S; La Rocca L; Nunnari CM; Barresi V
Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951
[TBL] [Abstract][Full Text] [Related]
24. Paraganglioma of the urinary bladder: a lesion that may be misdiagnosed as urothelial carcinoma in transurethral resection specimens.
Zhou M; Epstein JI; Young RH
Am J Surg Pathol; 2004 Jan; 28(1):94-100. PubMed ID: 14707870
[TBL] [Abstract][Full Text] [Related]
25. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
26. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract][Full Text] [Related]
27. The Utility of GATA3 in the Diagnosis of Urothelial Carcinomas With Variant Morphologic Patterns.
Verduin L; Mentrikoski MJ; Heitz CT; Wick MR
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):509-13. PubMed ID: 26317312
[TBL] [Abstract][Full Text] [Related]
28. GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall.
Akgul M; Humble R; Osme A; Yuce S; Kocak EN; Najafzadeh P; Sangoi A; Pattnaik N; Mishra S; Sharma S; Shaker N; Kaushal S; Baisakh M; Lightle AR; Balzer BL; Xiao GQ; MacLennan GT; Osunkoya AO; Parwani A; Cheng L; Bellizzi A; Mohanty SK
Diagn Pathol; 2022 Nov; 17(1):87. PubMed ID: 36320040
[TBL] [Abstract][Full Text] [Related]
29. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
30. The Diagnostic Dilemma of GATA3 Immunohistochemistry in Pheochromocytoma and Paraganglioma.
Kimura N; Shiga K; Kaneko K; Sugisawa C; Katabami T; Naruse M
Endocr Pathol; 2020 Jun; 31(2):95-100. PubMed ID: 32303954
[TBL] [Abstract][Full Text] [Related]
31. TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma.
Liu XL; Xue BX; Lei Z; Yang DR; Zhang QC; Shan YX; Zhang HT
Anat Rec (Hoboken); 2013 Nov; 296(11):1717-23. PubMed ID: 24124001
[TBL] [Abstract][Full Text] [Related]
32. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
33. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
34. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations.
Esheba GE; Longacre TA; Atkins KA; Higgins JP
Am J Surg Pathol; 2009 Mar; 33(3):347-53. PubMed ID: 19092634
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
Cox RM; Magi-Galluzzi C; McKenney JK
Adv Anat Pathol; 2018 Nov; 25(6):387-399. PubMed ID: 30157041
[TBL] [Abstract][Full Text] [Related]
36. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
37. Villous Morphology in Urinary Bladder Biopsy: An Approach to Diagnosis.
Mitra S; Ayyanar P; Kaur G
Int J Surg Pathol; 2020 Feb; 28(1):4-12. PubMed ID: 31409167
[TBL] [Abstract][Full Text] [Related]
38. Somatic-Type Yolk Sac Tumor Arising as a Predominant Component of Bladder Urothelial Carcinoma.
Collins K; Alkashash AM; Hwang M; Kaimakliotis HZ; Cheng L; Idrees MT
Int J Surg Pathol; 2022 Apr; 30(2):207-213. PubMed ID: 34255554
[TBL] [Abstract][Full Text] [Related]
39. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.
Sanfrancesco J; McKenney JK; Leivo MZ; Gupta S; Elson P; Hansel DE
Arch Pathol Lab Med; 2016 Jun; 140(6):543-51. PubMed ID: 27031776
[TBL] [Abstract][Full Text] [Related]
40. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.
Clark BZ; Beriwal S; Dabbs DJ; Bhargava R
Am J Clin Pathol; 2014 Jul; 142(1):64-71. PubMed ID: 24926087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
